Efficacy, Safety, and Net Clinical Benefit of Post‐Atrial Fibrillation Ablation Anticoagulation
Pacing and Clinical Electrophysiology · 2026-05 · 49 (5) · 590-601
DOI: 10.1111/pace.70224 ↗At a glance
Metaanalyse in Pacing and Clinical Electrophysiology, published online on 2026-03-26. Written by Mustafa Abomohsen and 12 co-authors. Institution: Department of Internal Medicine, Brookdale University Hospital, Brooklyn, New York, USA. Major MEDLINE topics: Atrial Fibrillation, Catheter Ablation, Anticoagulants, Thromboembolism. Cited 1 times so far (Crossref); 25 references.
Abstract (original language)
Background
The optimal long‐term antithrombotic strategy after apparently successful catheter ablation of atrial fibrillation (AF) remains uncertain, particularly in patients who meet conventional guideline thresholds for oral anticoagulation (OAC).
Objectives
To compare continuation versus cessation strategies of long‐term OAC after successful AF ablation and to quantify net clinical benefit (NCB) integrating thromboembolic and bleeding outcomes.
Methods
We searched PubMed, Cochrane CENTRAL, and Embase from inception through February 2026 for randomized and comparative observational studies evaluating long‐term OAC continuation versus cessation (no OAC and/or switch to aspirin) after successful AF ablation. Risk of bias was assessed using RoB2 for randomized trials and a modified Newcastle–Ottawa Scale (NOS) for observational studies. Random‐effects meta‐analyses used a restricted maximum likelihood estimator with Hartung–Knapp adjustment. NCB was calculated as: thromboembolic event rate − (1.5 × major bleeding rate).
Results
Six studies met the inclusion criteria (four randomized trials and two observational cohorts). Stroke/transient ischemic attack (TIA) events were reported in six studies and were not significantly different between OAC continuation and cessation strategies (OR 0.69; 95% CI 0.24–1.99; p = 0.49). Systemic embolism (three studies) did not differ between groups ( p = 0.12). Major bleeding (five studies) was numerically higher with continued OAC but not statistically significant (OR 2.07; 95% CI 0.88–4.86; p = 0.09). In NCB analysis, continued OAC yielded more negative or near‐neutral NCB values, whereas, the cessation strategies were less negative or marginally positive; the fixed‐effect risk difference in NCB (continued OAC vs cessation) was +0.00067 (95% CI −0.00279 to +0.00413).
Conclusion
This meta‐analysis suggests that after successful AF ablation, continuing OAC does not significantly reduce stroke risk compared to cessation or switching to aspirin, but it may increase major bleeding. While NCB trends favor cessation, the low absolute event rates and the risk of silent AF recurrence necessitate caution.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Internal Medicine, Brookdale University Hospital, Brooklyn, New York, USA.
- Department of Internal Medicine, Baptist Hospitals of Southeast Texas, Beaumont, Texas, USA.
- Department of Internal Medicine, Mayo Clinic, Jacksonville, Florida, USA.
- Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts, USA.
- Faculty of Medicine, Menoufia University, Menoufia, Egypt.
- Department of Internal Medicine, Wellington Regional Medical Center, Wellington, Florida, USA.
ORCID profiles: Mustafa Abomohsen, Ahmed Elmorsy Mohamed, Ahmed Farid Gadelmawla, Imad Samman Tahhan
Cite
APA
Abomohsen, M., Mohamed, A. E., Almakadma, A. H., Mojahedi, A., Kholeif, Z., Elalfy, A., Shams, M., Gadelmawla, A. F., Tahhan, I. S., Elnashar, M., Rashwan, R., Elnady, M., & Gunsburg, M. (2026). Efficacy, Safety, and Net Clinical Benefit of Post‐Atrial Fibrillation Ablation Anticoagulation. Pacing and Clinical Electrophysiology, 49(5), 590-601. https://doi.org/10.1111/pace.70224
Vancouver
Abomohsen M, Mohamed AE, Almakadma AH, Mojahedi A, Kholeif Z, Elalfy A, et al. Efficacy, Safety, and Net Clinical Benefit of Post‐Atrial Fibrillation Ablation Anticoagulation. Pacing and Clinical Electrophysiology. 2026;49(5):590-601. doi:10.1111/pace.70224
BibTeX
@article{Abomohsen2026,
author = {Abomohsen, Mustafa and Mohamed, Ahmed Elmorsy and Almakadma, Abdul Hakim and Mojahedi, Azad and Kholeif, Zeyad and Elalfy, Aya and Shams, Mahmoud and Gadelmawla, Ahmed Farid and Tahhan, Imad Samman and Elnashar, Mohab and Rashwan, Rana and Elnady, Mohamed and Gunsburg, Moshe},
title = {Efficacy, Safety, and Net Clinical Benefit of Post‐Atrial Fibrillation Ablation Anticoagulation},
journal = {Pacing and Clinical Electrophysiology},
year = {2026},
volume = {49},
number = {5},
pages = {590--601},
doi = {10.1111/pace.70224}
}
EUVIMED